Aarhus Universitet
Aarhus Universitet is recorded as a service provider in 91 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 91 trials · Latest update first
The effect of naldemedine on opioid-induced bowel dysfunction
Sponsor Aalborg University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
Multifactorial intervention to reduce cardiovascular disease in T1D
Sponsor Steno Diabetes Center Copenhagen
- Start (EU)
- Latest update
- Estimated end
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/MOIRAI)
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
Allogeneic adipose tissue-derived Mesenchymal stromal cells for the treatment of chronic-active antibody mediated rejection in Kidney transplant recipients
Sponsor Region Midtjylland
- Start (EU)
- Latest update
- Estimated end
- Not reported
Pomalidomide as an immune-enhancing agent for the control of HIV: An investigator-initiated phase I/IIb clinical trial in people living with HIV on ART and during analytical treatment interruption. (PEACH)
Sponsor Region Midtjylland
- Start (EU)
- Latest update
- Estimated end
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
Sponsor Oslo Universitetssykehus HF
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
The RIO Trial: A randomised placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary or Early stage HIV Infection on viral control off ART
Sponsor Imperial College London Limited
- Start (EU)
- Latest update
- Estimated end
EDULOX 2- Patientundervisning og medicinsk behandling (duloxetin/aktiv placebo) til patienter med svær funktionel lidelse: et randomiseret, kontrolleret forsøg.
Sponsor Region Midtjylland
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prednisone treatment in acute interstitial nephritis - a randomized prospective trial (PRAISE)
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
- Not reported
A study in healthy volunteers to help victims of nitrous oxide related crimes
Sponsor Aarhus Universitet
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Operational learnings available5 trial-level findings · Read insights
- Recruitment was conducted in Aarhus through trialtree.com.
- The 0.03 mL/L analytical detection limit meant all placebo N2O measurements were classified as zero, making the planned active-versus-placebo comparison impractical and necessitating descriptive analysis of the intervention group.
- Oral-fluid N2O analysis presented technical challenges and was considered a less viable biological matrix.
- Metabolomics analysis of potential longer-window biomarkers was deferred until approximately 1 January 2027.
- The continuous 50% N2O/50% oxygen exposure regimen differs from recreational pure, intermittent N2O inhalation, so forensic detection times may differ in real-world cases.
These findings describe the trial, not the service provider’s performance or responsibility.
INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED trial)
Sponsor Aarhus University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy Alone in Gastric Cancer Patients with Peritoneal Metastases
Sponsor Karolinska University Hospital
- Start (EU)
- Latest update
- Estimated end
Aspirin versus Aspirin and Fondaparinux Prior to Early Invasive Strategy in Patients with NSTEMI
Sponsor Region Midtjylland
- Start (EU)
- Latest update
- Estimated end
- Not reported
Luteal phase support following letrozole treatment in women undergoing intrauterine insemination: a multicenter randomized trial
Sponsor Region Midtjylland
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adipose-derived mesenchymal stem cells as local treatment of ulcerative colitis
Sponsor Region Midtjylland
- Start (EU)
- Latest update
- Estimated end
- Not reported
Targeting IL-13 in Bullous Pemphigoid: An Investigator-Initiated, Prospective, Multicenter, Proof-of-Concept, Open-Label Pilot Study of Lebrikizumab
Sponsor Region Midtjylland
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Early Detection of Hepatocellular Carcinoma by Hyperpolarized [1-13C]pyruvate MRI
Sponsor Aarhus Universitet
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)
Sponsor Vaestra Goetalandsregionen
- Start (EU)
- Latest update
- Estimated end
- Not reported
DANOHCA: The Danish Out-of-Hospital Cardiac Arrest study
Sponsor Rigshospitalet
- Start (EU)
- Latest update
- Estimated end
- Not reported
EUROpean pragmatic multicenter randomized trial on platelet inhibition and/or lipid lowering treatment in Covert Brain Infarction (CBI)
Sponsor Region Midtjylland
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Aarhus Universitet?
The 2026-10-09 snapshot links Aarhus Universitet to 91 distinct CTIS trials. Recorded services include Clinical monitoring, Quality assurance & auditing, Safety reporting & pharmacovigilance, Regulatory services, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Aarhus Universitet?
The most frequently recorded therapeutic areas are Immunology, Gastroenterology, Nephrology, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Aarhus Universitet conducted?
The linked trials record locations in 15 countries, including Denmark, Sweden, Norway, Germany, Spain. These are trial locations, not confirmed office locations or countries where Aarhus Universitet delivered services.
What can this page tell me about Aarhus Universitet's trial experience?
Browse 91 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Aarhus Universitet. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Aarhus Universitet